WLY - NYSE

Good morning, and welcome to Wallace Q3 Fiscal 2025 Earnings Call. As a reminder, this conference is being recorded. At this time, I'd like to introduce Wallace Vice President of Investor Relations, Brian Campbell. Please go ahead.

Thank you, and thank you all for joining us. On the call with me are Matthew Kissner, Wiley's President and CEO, Christopher Caridi, Interim CFO, and Jay Flynn, Executive Vice President and General Manager of Research and Learning. Note that our comments and responses reflect management's views as of today, and will include forward-looking statements. Actual results may differ materially from those statements. The company does not undertake any obligation to update them to reflect subsequent events. Also, Wiley provides non-GAAP measures as a supplement to evaluate underlying operating profitability and performance trends. These measures do not have standardized meanings prescribed by US GAAP and therefore may not be comparable to similar measures used by other companies. Nor should they be viewed as alternatives to measures under GAAP. Unless otherwise noted, we will refer to non-GAAP metrics on the call and variances are on a year-over-year basis and will exclude divested assets, and the impact of currency. Additional information is included in our filings with the SEC. A copy of this presentation and transcript will be available on our Investor Relations webpage at investors.wiley.com. I'll now turn the call over to Matthew Kissner.

Thank you, Brian. And good morning, everyone. Thank you for joining our third quarter update. We continue to capitalize on the increasing demand for scientific research and responsible AI development. We are executing well on our objectives of driving recovery and growth in research, and material margin expansion overall. And we remain on track to achieving our outlook for this year and next. In fact, we are raising our fiscal 2026 margin target. For those who may be new to the story, Wiley delivers authoritative content and data-driven insights to institutions, corporations, researchers, and learners. Our extensive catalog includes some of the most valuable and important content in the world, essential in the advancement of science, technology, and medicine. In the responsible development of AI and other machine learning applications, and in future high-value use cases supporting research and development such as science analytics, and information services. Let me acknowledge the economic uncertainty out there. Ranging from consumer confidence and inflation to tariffs, policy swings, and geopolitical unrest. As a reminder, for over two hundred years, Wiley has been a safe haven through many economic cycles and periods of disruption. We demonstrated this resiliency during the Great Recession and the COVID Pandemic. All publishing services, content, and brands remain must-have resources, and our markets continue to prosper. Supporting this is our strong balance sheet and consistent cash generation over time as evidenced by thirty-one consecutive years of dividend increases. What makes Wiley unique and compelling over the long term? As noted, our markets are robust. And demand remains consistent directly correlated with increasing global R&D investment. We recognize there's a wide business with essential, authoritative content and trusted brands. We deliver resilient compounding growth in markets that remain stable. Even during economic downturns. Approximately half of our revenues are recurring. In our research segment, this number is nearly seventy-five percent. We are an early AI beneficiary with emerging long-term opportunities in the corporate particularly in research and development. Our financial characteristics are strong, with healthy margins and cash generation, low leverage, and ample liquidity. And finally, the leadership team at Wiley is aligned and committed to continuous improvement and value creation. Let's talk about some of the favorable underlying trends we're seeing. First, global R&D spend continues as the primary driver of research out remaining strong in 2024 with growth of eight percent. Growth projections for 2025 are similar. Second, the demand to publish continues to increase reflecting its vital importance to the careers of researchers. Unitiate, research article submissions are up eighteen percent with publishing output up eight percent. Third, our recurring revenue models demonstrate strong health with solid pricing power supported by consistent recurring revenue models include our subscription read-only, and transformational read and publish agreements. Fourth, quality and scale matter. And Wiley excels in both areas. Quality has become more important than ever for research. As they seek to publish entrusted high-impact journals. At the same time, scale has become more important. Given the increasing complexity of this mixed model ecosystem with customers ranging from individual researchers to national governments. Our top-tier quality and scale give us an opportunity to have pace the market overall. Finally, Wiley's strategic position in AI development and application offers multiple advantages. As previously discussed, our content serves as a foundation for training large language models and bringing to market vertical-specific LLMs. Additionally, as a publisher, the nature of our work enables us to greatly benefit from AI product. Let me shift gears and focus on our headlines for the quarter. Revenue growth was driven by mid-single-digit growth in research, including an expanded AI licensing project with an existing technology customer. Learning was down due to challenging comparisons to the prior year, as discussed in our last earnings call. And some softness in academic books. Chris will go into further detail on our segment performance. Key takeaways from the quarter include our calendar 2025 journal subscription and TA renewal season is nearly eighty percent complete. And we are seeing encouraging growth trends. Open access continues to demonstrate rapid growth across our journal portfolio. We expanded a corporate AI licensing agreement this quarter and continue to build a pipeline of vertical-specific opportunities. It's very early days in the development of this vertical-specific market. But we're seeing considerable interest from leading research-intensive corporations. Margin expansion remains a multiyear strategic focus. And I'm pleased to report two hundred and eighty basis points of operating margin improvement and fifty basis points of adjusted EBITDA margin improvement over the prior year. As we will discuss later, we see significant opportunities for continued margin improvement. Chris will talk to our fiscal 2025 outlook and fiscal 2026 targets. But we see our EBITDA margin and EBS trending towards the high end of guidance and we're raising next year's margin target. Onto our results. Throughout my commentary, I'll exclude divested revenue was up one percent driven by research growth of five percent offsetting an expected six percent decline in learning. This year-over-year swing stemmed from a six million dollars licensing renewal in the prior year and softness this quarter in academic books. Adjusted EPS increased thirty-nine percent due to higher adjusted operating income and a lower adjusted effective tax rate. Our operating margin rose two eighty basis points to fourteen point two percent. Adjusted EBITDA grew four percent reflecting revenue growth partially offset by investments in growth and productivity initiatives. Our adjusted EBITDA margin for the quarter was twenty-three point two percent up from twenty-two point seven percent. Let's talk about how we are executing on our core objectives this year. First, driving recovery and growth in research. Year to date, this segment is up three percent with growth across all key areas, including our recurring revenue models, open access publishing program, licensing, and solutions. Leading indicators continue to be favorable. The expansion of our advanced journal franchise has been a great success. Sorry. This portfolio encompasses over twenty high-impact journal titles or course disciplines and we continue to expand in critical areas such as life sciences, AI, and machine learning. Our multidisciplinary journal Advanced Science is delivering exceptional growth this year. While our newest titles advanced intelligent discovery, and advanced robotics research recently published their inaugural articles. We anticipate launching additional advanced journals in 2025 and 2026. And as a reminder, top-tier journal franchises like Advance are differentiators for large publishers. Second, moving decisively on AI opportunities. Year to date, we've generated thirty million dollars in licensing revenue relating to trading models and executed an early but important agreement for vertical-specific models. This market is evolving and our pipeline remains very active. Third, driving continued margin improvement. Through nine months, our adjusted operating margin increased three thirty basis points to thirteen point three percent and adjusted EBITDA has improved by a hundred and sixty basis points to twenty-two point three percent. Let me say a few words about the current US funding environment. We're keeping a close eye on the potential impact of US government actions on research funding. We don't anticipate any near-term impact on our research publishing programs given the exceptional volume in our article pipeline, the lead times associated with any potential impact, and the recurring nature of our multiyear agreements. Importantly, as I'll describe in a moment, US federal funding only supports a small percentage of our research output. All of this is evident in today's confident reaffirmation of our fiscal 2025 outlook and fiscal 2026 targets, including the margin improvement. Moreover, it's too early to weigh any potential long-term impact given the high level of uncertainty and the critical importance of scientific, and technological activity in driving economic growth. Peer-reviewed research is how these advancements are communicated, evaluated, and applied. It is referred to as the global knowledge ecosystem. And Wiley stands at the center of it. Historically, this industry has advanced in good times and bad. It's always risen above politics, it's been excluded from tariffs and trade wars. And it's continued on even through conflict. It is an industry that is geographically well distributed and powered by many different funding sources. Every region participates with remarkable balance as illustrated here. For context, China leads as the number one source of research output worldwide followed by the U.S., the UK, Germany, and Japan. Governments in these countries consider dispositions strategically important contributing to Wiley's broad geographic diversification terms of regional breakouts, Asia Pacific is responsible for around forty-five percent of our article output. EMEA around thirty percent. North America around twenty percent, and other makes up about five percent. As for the US, direct federal funding is only responsible for a single-digit percentage of our total article output. Of course, we are fully confident that the US scientific, technical, and medical research will continue to receive federal support given the essential role that research plays in US economic growth, global competitiveness, and societal well-being. Where are we today? Mature markets have returned to steady growth supported by continued R&D investment, and growth markets have seen some remarkable new developments. Consider India's innovative one nation, one. We recently executed this multiyear agreement expanding access to over six thousand Indian institutions. And supporting eighteen million researchers and students. While this expansion increases profitable revenue for us, in India. Its significance extends beyond financial metrics. The agreement unifies the research ecosystem of the world's second most populated country. And as our India country lead, Ritesh Kumar, stated, it empowers Indian researchers to lead global scientific conversations and accelerate the country's research output. Our presence in India positions us well as these initiatives drive progress, and growth in Indian research. Similarly, in Brazil, we secured a new multiyear transformational agreement that expands access to over four hundred and thirty research, academic institutions. Reaching upwards of six million researchers. Both these landmark agreements serve strategic purposes that transcend immediate financial benefits. They expand access in emerging growth markets. And deliver additional revenue streams and ultimately enlarge both the scientific community and the global supply of quality research. Let's examine R&D and publication funding. Which shows similar geographic diversification. Our institutional models draw support from a diverse range of funding sources, including national governments, such as our single licenses in Germany and India, national funding bodies and agencies, state governments, private endowments, foundations, tuition revenue, and corporations. I'll emphasize again that nearly seventy-five percent of our research publishing revenue is recurring. Also, while many associate US R&D with federal government funding, corporations fund eighty percent of total US R&D investment. This reality reveals one of our most promising long-term opportunities. Currently, corporations represent a relatively small percentage of our overall revenue. However, we believe there is significant sustained value in integrating our content and data more deeply into the corporate research process. Such as AI, model enablement, and providing data and analytics to support the research process. Taken together, all these factors position research as both resilient and poised for continued expansion. To summarize, we continue to see growth this year in our recurring models and open access program. Renewals and leading indicators are favorable. And give us strong visibility. Over the long term, our quality and scale will remain essential elements for attracting and retaining research authors. And driving market share gains. Let's now turn to AI growth. Particularly the long-term corporate opportunity I mentioned earlier. This quarter, we executed an expanded agreement for AI model training purposes and we're seeing promising developments in the broader vertical-specific market. The agreement builds on the project announced in Q1 involving backlisted learning. This Q3 expansion incorporates backlist research content defined as previously published material older than three years. The nine million dollars agreement brings our total AI revenue this year to thirty million dollars following twenty-three million dollars realized last year. As a reminder, these phase one trading agreements are nonrecurring. It's important to reemphasize that licensing represents a core business activity for Wiley. As we take on new AI-specific initiatives, our guiding principles remain straightforward. We recognize our responsibility to engage with AI developers to secure scientific accuracy and deliver optimal learning outcomes. These models require training, untrusted, authoritative contents, such as Wiley's, while protecting the rights of authors and other copyright holders. A fundamental responsibility we embrace as a knowledge company. Beyond these large-scale training agreements, we're seeing encouraging demand from multinational including healthcare, R&D-centric companies across critical sectors biopharmaceuticals, and industrial chemistry. Distinct from our LLM training agreements, these R&D-intensive corporations are using AI-powered content and tools to speed up product development, identify breakthroughs, and reduce internal cycle times. And although the individual opportunities are mid materially smaller in size, they represent a much larger addressable market. And the revenue is highly likely to be recurring. Enhanced support for corporate research initiatives represents phase two of our content licensing strategy. With a broad set of applications across the many disciplines we. For these types of collaborations would extend beyond generating new licensing revenue streams to function as strategic partnerships enabling mutual learning about AI application development and its impact on improving research outcomes. The market will take time to fully develop, but we are encouraged by the early demand we're seeing. I'll now pass the call to Chris to take you through our year-to-date results, segment performance, outlook, and financial position.

Thank you, Matt. Good morning, everyone. Our results continue to align with expectations. Reinforcing our confidence in achieving our fiscal 2025 outlook and fiscal 2026 targets. Which I'll speak to shortly. Turning to our year-to-date results, adjusted revenue grew three percent driven by core growth in research and AI licensing. Excluding one-time AI-related revenue, overall revenue grew one percent. With research increasing two percent. We continue to advance our margin expansion initiatives resulting in significant improvements. Adjusted operating income up thirty-eight percent EPS up forty-three percent, and EBITDA up twelve percent. Our adjusted operating margin improved by three thirty basis points to thirteen point three percent and our adjusted EBITDA margin rose one hundred and sixty basis points to twenty-two point three percent. We continue to focus on optimizing our cost structure more specifically rightsizing our technology costs and other corporate expenses. At the same time, we're transforming how we publish, and work to drive greater operating efficiency. We do anticipate restructuring charges from this activity. Meanwhile, free cash flow shows strong recovery. And we remain on track to achieve one hundred and twenty-five million in fiscal 2025. Turning to our research segment, third quarter and year-to-date revenue increased five percent and three percent respectively. Q3 growth stemmed primarily from AI licensing and our open access programs. For the nine-month period, research publishing growth reflected strong demand to publish and read. With double-digit growth and gold open access, and low single-digit growth in our recurring revenue models, offsetting softness in ancillary products. A reminder that ancillary products include print, and other nonrecurring items such as back files, article pay-per-view, digital archives, and title-by-title journal sales to libraries. One-time AI licensing projects for backlisted content worth approximately ten million dollars year-to-date also contributed to our year-to-date results. Excluding these AI projects, research revenue is up two percent year-to-date. As Matt mentioned, we have completed nearly eighty percent of our calendar 2025 renewal season and see steady growth trends. The multi-year nature of these agreements means that around one-third of our library customers and come up for renewal annually. We have successfully renewed major agreements in the UK, France, and the US. While executing those new landmark deals in India, in Brazil. This renewal season extends from early December through the end of April 2025. Research Solutions have successfully returned to growth. With revenue increasing six percent in the quarter, and three percent year-to-date. Driven by expanded content solutions, and databases for societies, corporations, and other publishers. Wiley's key differentiator continues to be our enduring success in partnering with societies, and other professional organizations. Four of our key society health science partners have been with us for over fifty years. About forty-five percent have been with us for more than twenty. This remarkable retention rate demonstrates not only our shared success but also highlights one of our most valuable assets, our reputation. Partnerships like these are becoming increasingly multidimensional, with Wiley delivering a comprehensive suite of services, from publishing and content platforms to marketing and recruitment. Our IEEE partnership exemplifies this approach. As one of the world's largest societies responsible for a third of all technical literature, in electrical engineering and computing IEEE now benefits from Wiley's expanded role in managing their advertising sales and programs. This arrangement provides access to highly engaged audiences through impactful advertising, and digital content solutions. For Wiley, this partnership extends our participation in the engineering vertical leveraging our unique access to one of the world's most valuable professional audiences. Adjusted EBITDA for research increased twelve percent for the quarter and five percent year-to-date. Reflecting revenue growth, and cost savings partially offset by investments in growth and productivity. Our Q3 margin improved by one hundred and eighty basis points to thirty-two point seven percent while our year-to-date margin improved by thirty basis points to thirty-one point one percent. In summary, we are encouraged by our Q3 and year-to-date performance in research, and continue to anticipate a strong finish to the year. Let me now address our learning segment. In addition to challenging year-over-year comparisons, we saw moderate softness in academic book sales. While Q3 revenue decreased six percent, year-to-date revenue rose four percent. Driven by expansion in professional content, and AI licensing revenue. We continue to experience robust growth in signing new book titles across the science, technology, medicine, and professional fields. Additionally, our XiBook STEM courseware remains a strong growth driver. Adjusted EBITDA for the Learning segment decreased five percent this quarter reflecting revenue performance. Nevertheless, our margin expansion initiatives delivered thirty basis points of improvement resulting in an adjusted EBITDA margin of thirty-five point four percent. Year-to-date, our margin for learning improved by over four hundred basis points. To thirty-five point three percent. In summary, the year-over-year softness in Q3 aligned with our expectations. We continue to secure new business in our core areas, enhance margins, engaged in productive licensing discussions with AI developers. Turning to corporate unallocated expenses. These decreased five percent this quarter primarily due to lower excluding DNA, expenses increased nine percent reflecting the timing of investments in enterprise modernization, and consulting fees related to strategic initiatives including reengineering our cost structure. Notably, our segment margins improved both this quarter and year-to-date partly resulting from our reduced corporate allocated expenses. This demonstrates our continued progress in rightsizing our shared service costs and we have additional improvements planned. Let me now turn to our growth outlook. Our year-to-date execution, performance, and indicators remain solid. Enabling us to reaffirm our outlook in the mid to high end of our projected ranges. As previously noted, we anticipate a strong Q4 for our research segment driven by favorable journal renewals, and demand to publish indicators, as well as accelerating growth in research solutions and favorable comparisons to the prior year. These positive factors should more than offset the twenty-three million dollars non-recurring AI deal recorded in Q4 of last year. Also, as mentioned earlier, we are reassessing our cost structure with additional expected savings expected in fiscal 2026. To summarize, we expect full-year revenue to land near the midpoint of our one point six five billion dollars to one point six nine billion dollars range. Representing top-line growth of approximately three percent. Our segment outlook aligns with expectations with research revenue growing by low to mid-single digits and learning by low single digit. Adjusted EBITDA is expected to land near the midpoint between three hundred and eighty-five to four hundred and ten million. Translating to high single-digit growth. We anticipate our EBITDA margin to be at the high end of our twenty-three percent to twenty-four percent range. Adjusted EPS is expected to be at the high end of our three point two five dollars to three point six zero dollars range. Delivering strong double-digit growth over last year's two dollars seventy-eight cents. Finally, free cash flow is expected to meet our guidance of approximately one hundred and twenty-five million dollars an improvement from one hundred and fourteen million dollars in the prior year. While capital expenditures will come in lighter than initially projected, restructuring costs will be higher due to expanded cost reduction initiatives. Let's turn to the targets we first set down in January of 2024. Since that point, we've made decisive moves to improve our fundamentals and will continue to do so. Given our momentum in investments in research, our improved efficiency, and additional cost savings we are increasingly confident of our outlook for fiscal 2026. One, we continue to see revenue growth in the low to mid-single-digit range. Two, we are raising our margin target to be above twenty-five percent. From the original twenty-four percent to twenty-five percent range. We will be more specific when we discuss our full-year guidance in June. Three, we are reaffirming our free cash flow target of two hundred million up from one hundred and fourteen million dollars in fiscal 2024 and one hundred and twenty-five million projected for fiscal 2025. Let me walk you through the basic components of that improvement. As is illustrated here, we anticipate strong EBITDA growth next year. Given our revenue and margin outlook, lower restructuring costs, and improved working capital. Let me briefly conclude with our financial position and return to shareholders. Cash flow from operations and free cash flow year-to-date are much improved due to a mix of improved operating performance, and working capital timing. Free cash flow year-to-date has benefited from lower CapEx. Year-to-date, we continue to return cash to shareholders. With dividends and share repurchases totaling ninety-three million up from eighty-seven million in the prior year. Approximately thirty-five million was used to acquire seven hundred and eighty-four thousand shares. Our current dividend yield is over three point five percent. Finally, our net debt to EBITDA ratio was two point zero at the end of January compared to one point nine in the prior year period. The more appropriate time to look at this number is when we report April year-end in June. Last year we disclosed a leverage ratio of one point seven. With that, I'll pass it back to Matt.

Thank you, Chris. One final mention before I summarize our key takeaways. Yesterday, we announced that Doctor Karen Madden has joined the Wiley Board of Directors. Doctor Madden is the Senior Vice President and Chief Technology Officer at Millipore Sigma, the US and Canada life science business of Merck KGAA. Where she is responsible for shaping the technology roadmap and R&D strategy. Millipore Sigma develops products focused on scientific discovery, biomanufacturing, and testing services. As noted, Wiley's long-term strategy is increasingly focused on the corporate R&D value chain, and that Madden's wealth of knowledge and expertise in this area will be a tremendous addition. Okay. Let's review our key takeaways before we move on to questions. In periods of economic uncertainty, Wiley has consistently served as a safe haven delivering resilient compounding growth of course, economic cycles, and displaying geographic diversification significant competitive advantages, and strong financials. We will continue to move forward with operational discipline, fiscal prudence, and strategic foresight. We are an early beneficiary in AI development evolving alongside our corporate partners. We continue to explore various content opportunities for training, inference, and application. With an encouraging pipeline. As emphasized, content licensing represents a core business activity for us not merely an AI-specific initiative. Our execution remains strong with excellent organizational alignment yielding significant year-to-date improvements in both margins and cash flow and we maintain full confidence in our outlook for Q4 fiscal 2025 and fiscal 2026. With margin upside and a reaffirmed free cash flow target, of two hundred million dollars. I want to thank all of you for your interest and time today. I also extend my sincere appreciation for our Wiley colleagues. For their dedication and hard work in bringing us to this point and positioning us for even greater success in the future. I'll open the floor for questions.

Please press star then the number one on your telephone keypad. Your first question comes from the line of Daniel Moore with JR Securities. Please go ahead.

Yeah. Thanks. Good morning, Matt. Good morning, Chris. Thanks for all the details and color. Great to see the progress, you know, and upward revision regarding the 2026 margin target. Maybe just talk a little bit about the drivers. Is it additional cost savings? Incremental confidence on revenue, you know, AI, you know, expectations for incremental AI revenue, all the above, just what's driving the upward revision there.

Thanks, Dan. And, let me kick it off, and then I'll turn it over to Chris. But it's really primarily driven by working on the cost structure. And you know, it's really gratifying to see the ability to, with confidence, you know, really talk about these improvements coming through in our guidance. Really across the organization, we've been hard at work at let's say rationalizing the structure and getting back to what we would consider competitive margin levels. Let me turn it over to Chris who can give you a little more insight into that.

Yeah. Thanks, Matt. Dan, the primary driver, as Matt said, is that we are rationalizing our cost structure largely in corporate shared services. Been signaling that we were focused on this area. We see that we will begin execution on that in the latter part of this year, you'll see the benefit next year. That's a hundred plus basis point improvement we expect as a result of the actions we're taking.

Really helpful and yeah. We try again. Further. Go ahead.

You just real quick. You know, we want to create sustainable value here in terms of what I would call permanent margin improvement. So make these actions we're taking really count. So really, of course, the organization we're looking at the structure of footprint in certain places and really looking, you know, at getting excited at not only 2026, but even beyond to be showing really a continuous improvement mindset of around margins.

I think you just took the next question out of my mouth. You know, talking thinking about the longer-term opportunity, you know, what have you learned from, you know, competitors Springer, now that they're public, how do you compare and contrast your cost structure, and how do you think about the potential for, you know, more sustained margin upside going forward.

Yeah. We did a lot of benchmarking, including, of course, our competitors at Springer Nature and you know, it did point us to looking at structural cost differences. Now you do know that the mix of business is quite different from us. So they do we do have more of a society business in our mix than they do. So that has the royalty costs associated with it. But even when you back out the royalty cost, it points us in the direction that we do have an opportunity to streamline our cost structure. So you know, I think and we talked about this both you know, with the executive team and the board team here, and we are all looking at margin improvement as kind of a way of life. I think there is a lot of room for improvement there, but we want to do it in the right way, in a responsible way, and not interfere with the work we're doing on driving revenue growth.

Understood. Very helpful. Switching gears. The nine million incremental AI revenue just to confirm that the full nine million fell in Q3 and that was in research as opposed to the prior agreements which fell into learning. Correct?

That's correct, Dan. You have that right.

And that's perfect. It is switching gears again in terms of learning. Obviously, you know, you had a tough comp this quarter. Just talk about the outlook over the next, say, twelve months plus, you know, both academic and professional sides of the business and your confidence in getting back to positive growth in fiscal 2026 given, you know, some of the tougher comps you'll be up against particularly in the first half of the year.

Well, let Jay's on the call, so let him talk a little bit of kinda how he's looking at the business outlook and then Chris can give you a sense of the numbers.

Thanks, Matt and Dan. Yes. Nice to hear from you again. So, you know, we did indeed have a tough comp. I think if you exclude the AI revenue, though, from the last quarter, we were only off about a point in terms of prior year. And that points to, you know, some timing in the business a little bit of pressure in the retail channel. And a specific assumption around enrollments in the fall and spring semesters that just proved a little ambitious in terms of where we wanted to be this year. Right. Overall, I think, you know, the things I'd point to that give us some optimism and really underpinned, you know, the essence of what Matt was talking about and what we're doing, I'd point to improve margin and learning in the quarter as a key driver of that overall margin mix improvement that we're looking at. Growth in our

Chris, you wanna add anything?

Yeah. If I could. I don't want to specifically get into projections into 2026, but I'll just say relative to this Q4, we do have a tough comp coming up. Obviously, last year, we had a large Gen AI deal. We, if we remove out that deal, we would actually be talking about a very positive learning growth in Q4. Instead, we only see it coming down in the low to mid-single digits in Q4. And a lot of that is strength as Jay alluded to in the courseware, it's a big quarter for courseware. And it'll have an impact there. And, also, there are other licensing deals that we anticipate will mitigate to some degree, the large deal that we had in the prior year.

Does that answer your question, Daniel?

It does. That's helpful. And you alluded to the strength in, you know, some of the off the book signings, the author signings, etcetera. It should bode well for fiscal 2026. Maybe one more. You know, obviously bought back I think, thirty-five million in the quarter. You're looking at, you know, given the guidance somewhere in the, you know, over the next, call it, five quarters, you'll generate three hundred and thirty-five million plus of revenue of cash free cash flow. And that's, you know, obviously, pre-dividends, but still, you know, significant opportunity and leverage keeps going lower. So just talk about capital allocation near term, you know, stocks trade in sub ten times earnings, how you're thinking about buybacks versus paying down debt and any other uses of your cash flow. Thanks again for all the color.

Sure. Chris? Yeah. In the current year, we've been buying back at a larger excuse me, a higher rate than we had in the prior year. It's modest to some degree, but so is our cash flow improvement. Year over year. As we expand into the next year, we'll be taking a hard look at the pace of our share repurchases. There's no commitments at this point, but obviously, we'll have more free cash flow to make that assessment.

Anything else, Dave?

Before going to the next question, again, if you would like to ask a question? Your next question comes from the line of Sami Casa with BNP Paribas. Please go ahead.

Thank you very. First one, you yes. Describe?

Sam, you're breaking up.

We better now?

No. No. Yeah. No. I hope you can yes. So you described how the US already accounted for twenty percent of your Arctic count.

You a little bit elaborate on your revenue exposure to US institutions and in particular to US medical libraries? Given all the talks around NIH trending. The second question I may could you give a few examples of deploying AI internally helps improve cost efficiency. And can we discuss whether thanks to AI and tools, productivity gains can help improve margins. We talking about AI driving ten bps, or are we talking about AI and automation driving a hundred bps or more?

Yeah. I don't think we're gonna get to I'm sorry, Sammy. Go ahead.

And lastly, when I look at Elsevier or Springer or Informa, their research business is growing four percent to five percent organically. Do you think that research can accelerate towards four, five English short to medium term or the structural differences in exposure that perhaps may prevent that in the medium term. Thank you very much, Chen.

Yeah. Let me try to answer all of that, and I'm gonna ask Jay to step in at the right time. On the last question, you may have heard us on the prior call talk about the fact that we have a lot of our research revenue back-ended this year. Into the fourth quarter. You'll see that when we finish the year, we'll be research growth rates will be much more at industry levels. So that's the answer to the last question. On the percentage of we'll as you might imagine, we're monitoring the developments in the US are very carefully. And you know, when we look at the impact of some of the potential impact of some of the US funding actions, it really traces back to a low single-digit impact on us. And there are also, as you all know, many of these arrangements we have are in multiyear agreements. And there are time lags associated with the impact. And the fact is, right now, there are so many unknowns with how this is going to fall out in terms of policy changes and court challenges. So we're very confident about the business given its geographical diversification, I'll add on to that. So we're confident and confident enough to reaffirm our guidance. So but we are monitoring it and taking it very seriously. On the middle question about the AI impact, on kinda how we run the business, Jay and his team have some very, very exciting things underway. And we don't translate it into a particular financial impact at this point, but it's part of what's driving the overall margin improvement in the company. That we're committing to with our increased margin guidance. But, Jay, maybe touch on a couple of interesting areas where you're finding good with AI.

Yeah. Sure, Matt. And, Sami, thanks for the question. And thanks for the interest, of course. Let me just before I jump into AI, you asked about US medical library exposure. I just want to reiterate one of the two things that Matt said. You know, we in the prepared remarks, talked about how eighty-four percent of our content comes from outside the United States. And you know, that distribution of articles only it's a single-digit number. The tied directly to federal funding. And, of course, we anticipate a strong year, as Chris talked about, as we put in our guidance. Specifically with medical libraries, if I recall correctly, there's about a hundred and twenty academic medical centers in the United States. We have thousands of customers globally. And so while of course, we're monitoring what happens at those academic medical centers and those medical libraries. We feel good about a, the relationships long term that we have with those customers, and b, we feel good about the global nature of the business. So on that, no. Let me just pivot to the question a bit more. And as Matt points out, we are really we feel like we are driving and embracing AI both in the innovation side of the business and in the cost savings side. And you asked particularly about opportunities in cost. Certainly workflow automation document review, research integrity, automation of content workflows in particular are areas where we're spending a lot of time. We've got a group set up internally called the Magic Lab that we point at this kind of work, and they're working every day with folks inside the building and outside the building. We're bringing in experts to help us on this journey. But we feel really we feel very optimistic that, you know, two things. One, humans are gonna stay at the center of the AI work in our sector. Because of the importance of human and expert overview and review of the processes, and second, we feel like this is an area where we want to lead, and we want to continue to invest. And so you know, as a maybe as the key takeaway, Sami, I think, you know, our approach is ensuring that AI innovation is gonna happen with integrity, and we're gonna balance technology process with ethical stewardship, author engagement, and just a laser-like focus on both the top and the bottom line.

Thank you very much. Very helpful. Thank you.

Thank you, Sammy.

Again, if you would like.

If there are no other questions, operator, I can wrap up.

I will turn the call back over to Mister Kissner for closing remarks.

Thank you. Well, thank you, everyone. We appreciate you spending time with us. We appreciate your confidence. Again, I want to thank the Wiley colleagues around the world who have helped drive this terrific progress we're seeing, and we look forward to catching up with all of you again in June when we talk about the close of the fiscal year. Have a great day.